Difference between revisions of "Cortes JE, et al. Am. J. Hematol. (2018) cited as Ref 614 in DOI: 10.1038/s41392-020-0110-5 (Q9877)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 93, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results (English) | ||
| Property / title: Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:05, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Cortes JE, et al. Am. J. Hematol. (2018) cited as Ref 614 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Cortes JE
0 references
2018
0 references
Am. J. Hematol.
0 references
93
0 references
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results (English)
0 references
